Scientists at Sanford Burnham Prebys have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children.
Sanford Burnham Prebys Newsletter
Subscribe to our monthly email newsletter Discoveries.
Connect with us
Follow us on social media for the latest from Sanford Burnham Prebys.